{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:04:56Z","timestamp":1762254296165,"version":"3.37.3"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1124\/dmd.122.001000","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T12:28:04Z","timestamp":1667219284000},"page":"67-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Physiologically Based Pharmacokinetic Modeling for Quantitative Prediction of Exposure to a Human Disproportionate Metabolite of the Selective NaV1.7 Inhibitor DS-1971a, a Mixed Substrate of Cytochrome P450 and Aldehyde Oxidase, Using Chimeric Mice With Humanized Liver"],"prefix":"10.1016","volume":"51","author":[{"given":"Daigo","family":"Asano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Nishiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Shiozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Takakusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Shinozuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takakazu","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chizuko","family":"Yahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouichi","family":"Yoshinari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.122.001000_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/dmd.121.000665","article-title":"CYP2C8-mediated formation of a human disproportionate metabolite of the selective NaV1.7 inhibitor DS-1971a, a mixed cytochrome P450 and aldehyde oxidase substrate","volume":"50","author":"Asano","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001000_bib2","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1080\/00498254.2021.1963009","article-title":"Evaluation of species differences in the metabolism of the selective NaV1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase","volume":"51","author":"Asano","year":"2021","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.122.001000_bib3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/cts.12734","article-title":"Prediction of metabolite-to-parent drug exposure: Derivation and application of a mechanistic static model","volume":"13","author":"Callegari","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1124\/dmd.122.001000_bib4","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.122.001000_bib5","first-page":"239","article-title":"Comparison of p450 enzymes between cynomolgus monkeys and humans: p450 identities, protein contents, kinetic parameters, and potential for inhibitory profiles","volume":"14","author":"Emoto","year":"2013","journal-title":"Curr Drug Metab"},{"year":"2020","series-title":"Guidance for Industry: Safety Testing of Drug Metabolites. Center for Drug Evaluation and Research, U.S","key":"10.1124\/dmd.122.001000_bib6"},{"key":"10.1124\/dmd.122.001000_bib7","doi-asserted-by":"crossref","first-page":"21571","DOI":"10.1002\/anie.202004550","article-title":"Drug-like properties in macrocycles above MW 1000: Backbone rigidity versus side-chain lipophilicity","volume":"59","author":"Furukawa","year":"2020","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1124\/dmd.122.001000_bib8","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1124\/dmd.112.050294","article-title":"Application of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in\u2009vitro and in\u2009vivo data","volume":"41","author":"Gill","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001000_bib9","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1124\/dmd.111.042754","article-title":"Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver","volume":"40","author":"Hasegawa","year":"2012","journal-title":"Drug Metab Dispos"},{"year":"2010","series-title":"M3(R2) Guidance: Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals","key":"10.1124\/dmd.122.001000_bib10"},{"key":"10.1124\/dmd.122.001000_bib11","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2174\/138920008786485164","article-title":"Methods for predicting in\u2009vivo pharmacokinetics using data from in\u2009vitro assays","volume":"9","author":"Houston","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.122.001000_bib12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.dmpk.2020.07.004","article-title":"Human plasma concentration-time profiles of troglitazone and troglitazone sulfate simulated by in\u2009vivo experiments with chimeric mice with humanized livers and semi-physiological pharmacokinetic modeling","volume":"35","author":"Ito","year":"2020","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.122.001000_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2133\/dmpk.25.223","article-title":"Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites","volume":"25","author":"Kamimura","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.122.001000_bib14","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1124\/dmd.120.000128","article-title":"Prediction of human disproportionate and biliary excreted metabolites using chimeric mice with humanized liver","volume":"48","author":"Kato","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001000_bib15","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1124\/dmd.114.062620","article-title":"A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement","volume":"43","author":"Kazmi","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001000_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0168-3659(94)00118-E","article-title":"The effect of food on the gastrointestinal transit and systemic absorption of naproxen from a novel sustained release formulation","volume":"34","author":"Kenyon","year":"1995","journal-title":"J Control Release"},{"key":"10.1124\/dmd.122.001000_bib17","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1124\/dmd.111.040840","article-title":"Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton\u2019s tyrosine kinase inhibitor","volume":"39","author":"Liu","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001000_bib18","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3390\/pharmaceutics12111049","article-title":"Physiologically based pharmacokinetic\/pharmacodynamic modeling to predict the impact of CYP2C9 genetic polymorphisms, co-medication and formulation on the pharmacokinetics and pharmacodynamics of flurbiprofen","volume":"12","author":"Loisios-Konstantinidis","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1124\/dmd.122.001000_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/psp4.12049","article-title":"Good practices in model-informed drug discovery and development: Practice, application, and documentation","volume":"5","author":"Marshall","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.122.001000_bib20","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.bmc.2008.12.037","article-title":"Discovery of N-[(1R,2S,5S)-2-[(5-chloroindol-2-yl)carbonyl]amino-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: a novel, potent and orally active direct inhibitor of factor Xa","volume":"17","author":"Nagata","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/dmd.122.001000_bib21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1124\/dmd.115.068601","article-title":"Mechanistic modeling to predict midazolam metabolite exposure from in\u2009vitro data","volume":"44","author":"Nguyen","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001000_bib22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-3565(24)36999-X","article-title":"The prediction of human pharmacokinetic parameters from preclinical and in\u2009vitro metabolism data","volume":"283","author":"Obach","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.122.001000_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1124\/dmd.117.078279","article-title":"Estimation of circulating drug metabolite exposure in human using in\u2009vitro data and physiologically based pharmacokinetic modeling: Example of a high metabolite\/parent drug ratio","volume":"46","author":"Obach","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001000_bib24","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/toxsci\/kfm041","article-title":"Humanization of excretory pathway in chimeric mice with humanized liver","volume":"97","author":"Okumura","year":"2007","journal-title":"Toxicol Sci"},{"key":"10.1124\/dmd.122.001000_bib25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/pauz.200500150","article-title":"[Radioactive-labeled pharmaceutical agents]","volume":"34","author":"Pleiss","year":"2005","journal-title":"Pharm Unserer Zeit"},{"key":"10.1124\/dmd.122.001000_bib26","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1124\/dmd.112.047555","article-title":"Predictability of metabolism of ibuprofen and naproxen using chimeric mice with human hepatocytes","volume":"40","author":"Sanoh","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001000_bib27","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3109\/00498254.2015.1007112","article-title":"Predictability of plasma concentration-time curves in humans using single-species allometric scaling of chimeric mice with humanized liver","volume":"45","author":"Sanoh","year":"2015","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.122.001000_bib28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/00498254.2011.640716","article-title":"Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers","volume":"42","author":"Schulz-Utermoehl","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.122.001000_bib29","doi-asserted-by":"crossref","first-page":"10204","DOI":"10.1021\/acs.jmedchem.0c00259","article-title":"Discovery of DS-1971a, a potent, selective NaV1.7 inhibitor","volume":"63","author":"Shinozuka","year":"2020","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.122.001000_bib30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1021\/tx800415j","article-title":"Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment","volume":"22","author":"Smith","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.122.001000_bib31","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1124\/dmd.107.016188","article-title":"Interspecies prediction of human drug clearance based on scaling data from one or two animal species","volume":"35","author":"Tang","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001000_bib32","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3109\/00498254.2013.788232","article-title":"Prediction of human metabolism of the sedative-hypnotic zaleplon using chimeric mice transplanted with human hepatocytes","volume":"43","author":"Tanoue","year":"2013","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.122.001000_bib33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/labinvest.2012.158","article-title":"Morphological and microarray analyses of human hepatocytes from xenogeneic host livers","volume":"93","author":"Tateno","year":"2013","journal-title":"Lab Invest"},{"issue":"Suppl 3","key":"10.1124\/dmd.122.001000_bib34","first-page":"178","article-title":"Cell based experimental models as tools for the prediction of human intestinal absorption: Correlation with oral drug absorption and jejunal permeability in humans","volume":"40","author":"Tchaparian","year":"2008","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.122.001000_bib35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejpb.2009.07.007","article-title":"Magnetic marker monitoring: high resolution real-time tracking of oral solid dosage forms in the gastrointestinal tract","volume":"74","author":"Weitschies","year":"2010","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1124\/dmd.122.001000_bib36","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1124\/dmd.120.090928","article-title":"Drug-drug interaction risk assessment of esaxerenone as a perpetrator by in\u2009vitro studies and static and physiologically based pharmacokinetic models","volume":"48","author":"Yamada","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001000_bib37","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1208\/s12248-009-9124-1","article-title":"Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships","volume":"11","author":"Yang","year":"2009","journal-title":"AAPS J"},{"key":"10.1124\/dmd.122.001000_bib38","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3109\/00498254.2012.656732","article-title":"Characterization of intestinal and hepatic P450 enzymes in cynomolgus monkeys with typical substrates and inhibitors for human P450 enzymes","volume":"42","author":"Yoda","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.122.001000_bib39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2125.1998.00653.x","article-title":"Improvement in the gastrointestinal absorption of troglitazone when taken with, or shortly after, food","volume":"45","author":"Young","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001000_bib40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0378-5173(98)00174-4","article-title":"Characterization of small intestinal transit time distribution in humans","volume":"171","author":"Yu","year":"1998","journal-title":"Int J Pharm"},{"key":"10.1124\/dmd.122.001000_bib41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0378-5173(99)00147-7","article-title":"A compartmental absorption and transit model for estimating oral drug absorption","volume":"186","author":"Yu","year":"1999","journal-title":"Int J Pharm"},{"key":"10.1124\/dmd.122.001000_bib42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/00498250110092423","article-title":"Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in\u2009vitro: implications for prediction of metabolic interactions in\u2009vivo","volume":"32","author":"Zhou","year":"2002","journal-title":"Xenobiotica"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624009139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624009139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.122.001000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:58:20Z","timestamp":1739955500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624009139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0090955624009139"],"URL":"https:\/\/doi.org\/10.1124\/dmd.122.001000","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically Based Pharmacokinetic Modeling for Quantitative Prediction of Exposure to a Human Disproportionate Metabolite of the Selective NaV1.7 Inhibitor DS-1971a, a Mixed Substrate of Cytochrome P450 and Aldehyde Oxidase, Using Chimeric Mice With Humanized Liver","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.122.001000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}